SE8704204L - Substituerade alfa-aminosyror, deras framstellning och farmaceutiska kompositioner innehallande desamma - Google Patents

Substituerade alfa-aminosyror, deras framstellning och farmaceutiska kompositioner innehallande desamma

Info

Publication number
SE8704204L
SE8704204L SE8704204A SE8704204A SE8704204L SE 8704204 L SE8704204 L SE 8704204L SE 8704204 A SE8704204 A SE 8704204A SE 8704204 A SE8704204 A SE 8704204A SE 8704204 L SE8704204 L SE 8704204L
Authority
SE
Sweden
Prior art keywords
preparation
amino acids
pharmaceutical compositions
compositions containing
substituted
Prior art date
Application number
SE8704204A
Other languages
English (en)
Swedish (sv)
Other versions
SE466311B (sv
SE8704204D0 (sv
Inventor
P L Herrling
W Muller
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of SE8704204D0 publication Critical patent/SE8704204D0/xx
Publication of SE8704204L publication Critical patent/SE8704204L/
Publication of SE466311B publication Critical patent/SE466311B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE8704204A 1986-10-30 1987-10-28 Substituerade alfa -aminosyror, deras framstaellning och farmaceutiska kompositioner innehaallande desamma SE466311B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868625941A GB8625941D0 (en) 1986-10-30 1986-10-30 Substituted alpha-amino acids

Publications (3)

Publication Number Publication Date
SE8704204D0 SE8704204D0 (sv) 1987-10-28
SE8704204L true SE8704204L (sv) 1988-05-01
SE466311B SE466311B (sv) 1992-01-27

Family

ID=10606531

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8704204A SE466311B (sv) 1986-10-30 1987-10-28 Substituerade alfa -aminosyror, deras framstaellning och farmaceutiska kompositioner innehaallande desamma

Country Status (27)

Country Link
US (1) US5162311A ( )
JP (2) JPH0641475B2 ( )
KR (1) KR950004960B1 ( )
AT (1) AT393384B ( )
AU (1) AU614726B2 ( )
BE (1) BE1002421A4 ( )
CA (1) CA1310331C ( )
CH (1) CH677794A5 ( )
CY (1) CY1703A ( )
DE (1) DE3736016C2 ( )
DK (1) DK565987A ( )
ES (1) ES2012521A6 ( )
FI (1) FI87222C ( )
FR (1) FR2606018B1 ( )
GB (2) GB8625941D0 ( )
GR (1) GR871659B ( )
HK (1) HK110393A ( )
HU (1) HU200465B ( )
IE (1) IE59310B1 ( )
IL (1) IL84302A ( )
IT (1) IT1212033B ( )
LU (1) LU87031A1 ( )
NL (1) NL8702485A ( )
NZ (1) NZ222333A ( )
PT (1) PT86018B ( )
SE (1) SE466311B ( )
ZA (1) ZA878176B ( )

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395827A (en) * 1986-04-09 1995-03-07 Guilford Pharmaceuticals Inc. ω-[2-(phosphonoalkyl)phenyl]-2-aminoalkanoic acids as antagonists of excitatory amino acid receptors
US4918064A (en) * 1987-10-21 1990-04-17 G. D. Searle & Co. Phenyl glycines for use in reducing neurotoxic injury
US5175153A (en) * 1987-11-30 1992-12-29 Warner-Lambert Company Substituted alpha-amino acids having pharmaceutical activity
FR2634763B1 (fr) * 1988-08-01 1991-07-12 Inst Nat Sante Rech Med Amino-acides et peptides presentant un residu tyrosine modifiee, leur preparation et leur application comme medicaments
US5177240A (en) * 1988-10-21 1993-01-05 G. D. Searle & Co. O-phosphono(alkyl)-n-sulfonyl-phenyl-alanine derivatives useful as intermediates for preparation of phosphono-hydroisoquinolines
US4997821A (en) * 1988-10-21 1991-03-05 Cordi Alexis A Phosphono-hydroisoquinoline compounds useful in reducing neurotoxic injury
US5100654A (en) * 1989-04-07 1992-03-31 Yale University Phosphorylated derivatives of l-dopa and compositions and methods for increasing the melanin content in mammalian skin and hair
DE3940410A1 (de) * 1989-12-04 1991-06-06 Schering Ag Neue verwendung von nmda-rezeptor-antagonisten
US5238958A (en) * 1990-02-26 1993-08-24 Warner-Lambert Company Substituted α-amino acids having selected acidic moieties for use as excitatory amino acid antagonists in pharmaceuticals
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5264607A (en) * 1991-09-30 1993-11-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Process of making benzylic α,α-diflurophosphonates from benzylic α-ketophosphorates
US5475129A (en) * 1991-09-30 1995-12-12 The United States Of America As Represented By The Department Of Health And Human Services Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis
US5200546A (en) * 1991-09-30 1993-04-06 The United States Of America As Represented By The Department Of Health And Human Services Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis
GB9325360D0 (en) * 1993-12-10 1994-02-16 Univ Bristol Organic compounds
US5489717A (en) * 1994-07-08 1996-02-06 Warner-Lambert Company Glutamate (NMDA) receptor antagonists
GB9423019D0 (en) * 1994-11-15 1995-01-04 Sandoz Ltd Improvements in or relating to organic compounds
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
US6133281A (en) * 1996-10-24 2000-10-17 Harbor-Ucla Research And Education Institute NMDA receptor blockers in the therapy of urogenital disease
ATE265213T1 (de) * 1997-09-04 2004-05-15 Novoneuron Inc Noribogain zur behandlung von schmerzen und drogenabhängigkeit
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
SE9804064D0 (sv) 1998-11-25 1998-11-25 A & Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
MY140707A (en) * 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
DE10328260A1 (de) * 2003-06-23 2005-01-27 Schmidt, K.-G., Dr. med. Flupirtine-Präparat
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
BR112012031107A2 (pt) 2010-06-09 2017-07-25 Queen Mary & Westfield College molécula de ligação específica cultivada contra a proteína anx-a1 humana, linha de células de hibridoma, composição farmacêutica , uso da molécula de ligação específica e método para o tratamento de uma doença mediada por linfócitos t em um indivíduo com necessidade do mesmo
GB201121564D0 (en) * 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
GB201702091D0 (en) 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE550634A ( ) * 1955-08-30
BE626546A ( ) * 1961-12-30
DE2459491A1 (de) * 1974-12-17 1976-06-24 Bayer Ag Gegenueber isocyanaten reaktive phosphorhaltige flammschutzmittel
US4657899A (en) * 1986-04-09 1987-04-14 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid neurotransmitter receptors
US4761405A (en) * 1987-03-04 1988-08-02 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid neurotransmitter receptors having increased potency
US4918064A (en) * 1987-10-21 1990-04-17 G. D. Searle & Co. Phenyl glycines for use in reducing neurotoxic injury

Also Published As

Publication number Publication date
FR2606018A1 (fr) 1988-05-06
HUT47949A (en) 1989-04-28
IL84302A (en) 1993-06-10
DE3736016C2 (de) 1995-04-20
PT86018B (pt) 1990-07-31
IT1212033B (it) 1989-11-08
FI874761A (fi) 1988-05-01
IL84302A0 (en) 1988-03-31
SE466311B (sv) 1992-01-27
CY1703A (en) 1994-01-14
NZ222333A (en) 1990-09-26
AU614726B2 (en) 1991-09-12
HU200465B (en) 1990-06-28
GB8625941D0 (en) 1986-12-03
US5162311A (en) 1992-11-10
BE1002421A4 (fr) 1991-02-05
KR950004960B1 (ko) 1995-05-16
SE8704204D0 (sv) 1987-10-28
ES2012521A6 (es) 1990-04-01
LU87031A1 (fr) 1988-05-03
IE59310B1 (en) 1994-02-09
NL8702485A (nl) 1988-05-16
KR890006661A (ko) 1989-06-15
CA1310331C (en) 1992-11-17
FI87222B (fi) 1992-08-31
DK565987A (da) 1988-05-01
AU8040487A (en) 1988-05-05
DK565987D0 (da) 1987-10-28
DE3736016A1 (de) 1988-05-05
ZA878176B (en) 1989-06-28
ATA285187A (de) 1991-03-15
AT393384B (de) 1991-10-10
PT86018A (en) 1987-11-01
GB2198134A (en) 1988-06-08
FR2606018B1 (fr) 1990-11-16
GB8724186D0 (en) 1987-11-18
GR871659B (en) 1988-03-03
GB2198134B (en) 1990-07-04
IE872908L (en) 1988-04-30
JPH0641475B2 (ja) 1994-06-01
FI874761A0 (fi) 1987-10-29
CH677794A5 ( ) 1991-06-28
JPH03101685A (ja) 1991-04-26
FI87222C (fi) 1992-12-10
HK110393A (en) 1993-10-29
IT8748544A0 (it) 1987-10-28
JPS63122693A (ja) 1988-05-26

Similar Documents

Publication Publication Date Title
SE8704204L (sv) Substituerade alfa-aminosyror, deras framstellning och farmaceutiska kompositioner innehallande desamma
IL107884A0 (en) Sulphonamides, their manufacture and pharmaceutical compositions containing them
ES2100907T3 (es) Bencimidazoles, medicamentos que contienen estos compuestos y proced imiento para su preparacion.
MX9307810A (es) Heterociclicos no aromaticos sustituidos con aminometileno.
ITRM910696A1 (it) Composizioni farmaceutiche per l'applicazione per via nasale.
EP0446570A3 (en) Gabapentin and its derivatives for treating neurodegenerative diseases
IT8025023A0 (it) Attrezzo per l'erogazione di masse ad uno o piu' componenti.
DE59203976D1 (de) Hydantoinderivate.
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
FI945975A0 (fi) Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
FI881609A (fi) Dihydropyridinamider, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
GR77719B ( )
GR3021303T3 (en) Benzimidazoles, pharmaceutical compositions containing them and process for their preparation
FI903701A0 (fi) Reninhaemmande amino-oligohydroxiderivat.
ES2065745T3 (es) Sintesis de compuestos de 1alfa-hidroxi-secosterol.
DK0381114T3 (da) Exo-3,4-O-benzyliden-3"-demethylchartreusin og salte deraf
DK0412941T3 (da) Phospholipider til behandling af dissemineret sklerose

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8704204-0

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8704204-0

Format of ref document f/p: F